Cernos

Quick links to important sections

Cernos

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cernos

Cernos: What Type of Medicine Is It? (Classification and Identity)

Cernos is a specific brand primarily containing the active ingredient Testosterone Undecanoate. It is classified as an Androgen and a Hormone Replacement Therapy agent, falling under the broader category of Anabolic-Androgenic Steroids (AAS). The substance is a synthetic androstane steroid and an ester derivative designed to correct deficiencies in male hormone levels. This classification reflects its function in treating hormonal imbalance as an androgen used for replacement therapy.

This medicine functions as a prodrug, distinguishing it within the pharmacological class of hormones. Its fundamental purpose is to serve as an external source for testosterone, providing a controlled and stable replenishment of deficient testosterone levels within the body. The goal is to bring the overall hormonal profile of the adult male back into a healthy, physiological range, supporting functions dependent on adequate levels of the male sex hormone.

Active Ingredient and Drug Forms (Composition and Delivery)

The core component is Testosterone Undecanoate, which is the active ingredient and the source material for the eventual release of native testosterone. The Cernos brand offers both the softgel capsule for oral administration and the longer-acting intramuscular injection (often described as a depot form). The oral softgel capsule form is formulated to be absorbed through the lymphatic system, allowing for effective systemic delivery.

This compound is highly lipophilic, and its delivery systems are tailored for effective absorption, requiring an oil base (oleaginous vehicle) for the capsules and the depot injection suspension. The undecanoate ester structure is engineered to resist rapid degradation, ensuring the medicine’s action is prolonged as it gradually releases the active hormone following enzymatic ester cleavage within the circulation, helping to restore testosterone balance.

What side effects are possible with Cernos?

Possible Side Effects and Safety Information

The safety profile for Testosterone Undecanoate (Cernos) is formally structured around common adverse reactions associated with androgen exposure and specific serious risks, as documented in governmental regulatory labeling.

Officially Documented Adverse Reactions

The most frequently observed adverse reactions are classified as Common (appearing in 2% of clinical trial subjects or defined as such in official labeling) and often involve systemic androgenic effects, the vascular system, and general bodily changes. These include increased hematocrit (polycythemia), hypertension (blood pressure increase), acne, headache, musculoskeletal pain, gynecomastia, and increases in Prostatic Specific Antigen (PSA).

Serious Adverse Reactions

Official documents highlight the potential for serious adverse reactions. These include the risk of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). For the injectable form, there is a documented risk of Pulmonary Oil Microembolism (POME) reactions and Anaphylaxis (severe allergic reaction), which may occur during or immediately after administration. Furthermore, the label notes the association between increased blood pressure and the potential for Major Adverse Cardiovascular Events (MACE).

Population-Specific Safety Notes

The safety profile includes restrictions for specific groups. The medicine is contraindicated in women who are pregnant. Older adults may face an increased risk of worsening Benign Prostatic Hyperplasia (BPH) and hypertension. Patients with pre-existing cardiac, renal, or hepatic disease carry an elevated risk of experiencing edema (fluid retention).

Overdose and Emergency Response

The official regulatory documents indicate that specific information on acute Cernos overdose is limited; however, the profile details severe risks associated with chronic supra-therapeutic use and acute reactions to the injectable form.

Overdose resulting from high, prolonged exposure is associated with serious outcomes affecting multiple physiological systems. These documented manifestations include cardiac arrest, myocardial infarction, and cerebrovascular accident (stroke), along with potential hepatotoxicity. Psychiatric manifestations, such as mania or paranoia, and elevated serum testosterone concentrations are also officially noted.

Acute, life-threatening events specific to the intramuscular injection include Pulmonary Oil Microembolism (POME) reactions and Anaphylaxis. These events may present with signs such as dyspnea (trouble breathing), chest pain, or syncope (fainting). For these severe, acute symptoms, regulators explicitly state the need to seek immediate medical attention.

In all suspected overdose situations, the required actions involve discontinuation of therapy and management through symptomatic and supportive measures, as no specific antidote is known. Due to acute risks, the label mandates that patients receiving the intramuscular injection must be observed in the healthcare setting for 30 minutes following each administration. Monitoring serum testosterone levels is required if supra-therapeutic use is suspected.

Therapeutic Uses of Cernos

What Cernos Treats: Main Uses and Benefits

Cernos contains Testosterone Undecanoate and is commonly used for Testosterone Replacement Therapy (TRT) in adult males. The medication is considered relevant in clinical settings marked by the deficiency or absence of endogenous testosterone, a condition medically defined as Male Hypogonadism or Testosterone Deficiency Syndrome (TDS). Use of this medication aligns with the treatment of conditions associated with a deficiency or absence of endogenous testosterone.


Therapeutic Scope and Patient Benefit

The therapy is used for managing symptom clusters that may become intense or disruptive, including decreased libido, erectile dysfunction due to low-T, fatigue, low mood, and loss of muscle mass. Cernos is commonly used to help with symptoms related to systemic imbalance and chronic hormone deficiency, providing supportive relief when symptoms interfere with routine activities.

This makes it relevant for easing symptom clusters that interfere with daily functioning and physical stability. The medication may support the patient's general well-being and may help them cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Imbalance

The medication is commonly used across conditions presenting with chronic manifestations of a hormone deficit. It contributes to easing the overall symptom load related to a diagnosed hormone deficiency.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cernos?

This section outlines the officially documented population eligibility rules for Cernos (Testosterone Undecanoate), based strictly on government regulatory documents.


Contraindicated Populations (Absolute Prohibitions)

The medicine is contraindicated and must not be used by females under any circumstances. It is also prohibited for adult males with known or suspected carcinoma of the prostate or carcinoma of the breast. Use is also contraindicated in individuals with a known hypersensitivity to the active ingredient or any excipients.

Age-Group and Condition Restrictions

Population Group Regulatory Status
Pediatric Use (< 18) Use is not recommended; safety and efficacy are not established due to risks to bone development.
Geriatric Use (> 65) Use is permitted, but requires close monitoring for worsening prostate conditions.
Pregnancy/Lactation Contraindicated in pregnant and breastfeeding women.

Eligibility is further constrained for patients with severe pre-existing cardiac, renal, or hepatic disease, particularly when associated with oedema (fluid retention). Use is also not recommended for men with uncontrolled hypertension or unmonitored severe sleep apnoea. These restrictions are defined in official product labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This profile details the officially documented interactions for Cernos (Testosterone Undecanoate) as established by government regulatory authorities.


Interaction Scope

  • Medicinal product categories with documented interactions: Corticosteroids, Oral Anticoagulants, and Anti-diabetic Agents (both insulin and oral forms).
  • Timing-based interaction rules: For the oral capsule formulation, co-administration with food is a mandatory requirement for adequate systemic absorption. No specific time separation rules are documented for drug-drug combinations.
  • Population-specific interaction notes: The risk of fluid retention when combined with corticosteroids is heightened in patients with pre-existing cardiac, renal, or hepatic disease, necessitating careful monitoring.

Interaction Classifications (High-Level)

  • Interaction severity classification: Interactions requiring careful monitoring and potential dose adjustment (Anticoagulants, Anti-diabetic Agents).
  • Interaction-related restrictions: No drug-drug combinations are formally classified as contraindicated due to interaction risk. The use of Oral Anticoagulants requires mandated monitoring of the patient's INR.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Corticosteroids may cause a pharmacodynamic reinforcement resulting in increased fluid retention.
  • Testosterone Undecanoate may cause changes in anticoagulant activity, requiring frequent monitoring of the International Normalized Ratio (INR).
  • The medicine may lead to a reduction in blood glucose levels, which can affect the required dosage of co-administered anti-diabetic agents.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure based on clinically relevant pharmacodynamic reinforcement and altered therapeutic exposure of co-administered agents. The profile mandates specific monitoring protocols for combinations like anticoagulants and highlights a critical administration constraint regarding the necessary co-administration of the oral capsule form with food. The structure is further constrained by specific warnings regarding interaction severity in patients with pre-existing conditions.

Mechanism of Action

How Cernos Works: Mechanism of Action

Cernos provides exogenous testosterone, a molecule identical to the naturally occurring hormone, which enters circulation and acts to modulate specific receptor systems.

Direct Androgen Receptor Activation

The active component functions as an agonist that directly binds to and activates Androgen Receptors (AR) throughout various tissues. This molecular cascade involves the activated hormone-receptor complex entering the cell nucleus to modulate gene transcription. This action influences cellular processes in target tissues, including muscle and bone.

Modulating Anabolism and Systemic Feedback

Regulation of gene expression influences the transcription of genes associated with protein synthesis and degradation, thereby supporting protein anabolism. Systemically, the presence of the hormone exerts negative feedback on the central Hypothalamic-Pituitary-Gonadal (HPG) axis, which modulates the body's endocrine feedback mechanisms. These actions are associated with the molecular and cellular events that influence the structure of musculoskeletal tissue and modulate the activity of systems governing sexual and metabolic regulation.

Dosage and Administration Information

Cernos (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males with hypogonadism due to a deficiency or absence of endogenous testosterone. The proper use of this oral capsule is critical for ensuring therapeutic benefit and reducing potential risks.

Administration and Dosing

  • Confirm Diagnosis: Before initiating treatment, the diagnosis of hypogonadism must be confirmed by measuring serum testosterone concentrations on at least two separate morning measurements, ensuring they are below the normal range.
  • Take with Food: Cernos capsules must be taken with a meal (food) to ensure adequate absorption of the active ingredient. Do not crush, chew, or break the capsule; swallow it whole with water.
  • Timing: The daily dosage is typically divided and administered twice daily, once in the morning and once in the evening. If the prescribed daily dose requires an uneven split, the larger portion is often taken in the morning.
  • Dosage Adjustment: The dose is individualized based on the patient's serum testosterone concentration response. Your healthcare provider will measure serum testosterone levels approximately seven days after starting treatment or following a dose adjustment. This measurement is typically taken 3–6 hours after the morning dose.

Important Monitoring

Regular monitoring is necessary to evaluate the safety and efficacy of Cernos. Your doctor will periodically check for adverse effects by monitoring:

  • Hematocrit/Hemoglobin: To detect increases in red blood cell mass (polycythemia), which may require dose reduction or cessation of therapy.
  • Prostate-Specific Antigen (PSA): Monitoring for potential worsening of benign prostatic hyperplasia (BPH) or the risk of prostate cancer.
  • Testosterone Levels: To ensure the serum concentration remains within the target therapeutic range.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Foundational Studies and Characteristics

Foundational research evaluated the compound's characteristics relevant to two key pathways implicated in the condition's progression. These studies, primarily conducted in vitro and in animal models, investigated the substance's properties. The focus was on dose-response characteristics in isolated tissues to inform later human trials.

Efficacy and Outcome Trials

Clinical studies investigated the potential characteristics of the compound when administered to human volunteers.

Phase I and II Trials

Early-stage human trials focused on establishing initial dose levels and observation of tolerance. Phase I focused on dose levels and observed how the compound was tolerated in initial human studies. Phase II trials evaluated whether the compound demonstrated a relationship with changes in the frequency of acute episodes.

  • Primary Goal: To identify dose ranges suitable for large-scale investigation and to gather preliminary information on the compound's behavior in the body.
  • Timing of Observation: Studies also examined the time needed to observe potential changes in symptoms.

Phase III Clinical Trials

The registration trials were designed as double-blind, randomized, controlled studies comparing the investigational compound to a placebo or active comparator.

  • Study A (Primary Endpoint): The main objective of this study was to investigate measurements related to overall respiratory function. The first study reported measurements related to symptom severity over the duration of the trial.
  • Study B (Comparative Trial): This trial specifically evaluated whether the compound demonstrated a relationship with changes in inflammation markers. This study also compared the outcomes to those observed in patients receiving standard treatment.
  • Research Scope: Investigators tracked events and laboratory changes across the treatment groups as part of the study monitoring process.

Frequently Asked Questions (FAQ)

Common questions about Cernos (FAQ)


Q: Are there any common foods or drinks that should be avoided while using Cernos?

Official prescribing information requires the oral capsule form of Cernos to be taken with a meal to ensure the medicine is properly absorbed by the body. Beyond this specific administration requirement, regulatory documents do not list specific foods or non-alcoholic drinks as being prohibited or needing to be specifically avoided.


Q: Is Cernos considered a controlled substance?

Yes, the active ingredient in Cernos, testosterone, is categorized as a Schedule III controlled substance under the U.S. Controlled Substances Act. The Schedule III classification is used by regulatory bodies to denote substances with an accepted medical use but also a potential for abuse or dependence.


Q: Does Cernos have a risk of dependence or addiction?

Regulatory documents state that when Cernos is used at approved therapeutic doses, drug dependence has not been documented. However, official documents note that the abuse of testosterone products, typically involving doses higher than prescribed, has been associated with addiction behaviors and withdrawal symptoms upon abrupt discontinuation.


Q: Do older adults use Cernos differently than younger people?

The general administration instructions are the same for all adults. However, official documents highlight that older patients may have an increased risk of worsening existing prostate issues, such as Benign Prostatic Hyperplasia (BPH), and increased blood pressure. Because of these specific risks, official documents recommend close monitoring for geriatric patients.


Q: Does Cernos cause hair loss or growth?

As a type of androgen, the medicine is associated with effects on male characteristics. Regulatory safety profiles for testosterone products mention both potential increased hair growth (hirsutism) and the potential for male-pattern baldness as reported effects.


Q: What happens to the body when Cernos is stopped?

For approved use, regulatory texts suggest that stopping the medicine may be associated with the return of symptoms related to the underlying hormone deficiency. Individuals who have misused or abused the medicine at very high doses may experience withdrawal symptoms upon cessation.


Q: Can Cernos be used by minors?

Official product information states that use is not recommended in pediatric patients (minors or those under 18 years of age). This restriction is in place because the safety and efficacy have not been established in this age group, and there is a risk of accelerating bone maturation, which could compromise the final adult height.


Q: Are there different strengths or concentrations of Cernos?

Yes, official prescribing information confirms that the oral capsule form is available in several different strengths. The prescribed strength is determined by a healthcare provider based on the clinical assessment of the patient's needs.


Q: What is the longest period of time people typically use Cernos?

Since the medicine is used to treat a deficiency or absence of the natural hormone, it is typically understood to be a long-term therapy or replacement treatment. Medical studies have reported following patients who have used the medicine for periods exceeding ten years.


Q: Can Cernos affect cholesterol levels?

Official safety documents indicate that this medicine may cause changes in the level of cholesterol and fats (lipids) in the blood. For this reason, patients on this therapy often have their lipid profiles monitored periodically.


Q: Does Cernos affect my ability to drive or operate machinery?

Official safety information notes potential side effects such as headache and dizziness. Patients who experience these effects may have an altered ability to perform tasks requiring full attention.


Q: Is Cernos a brand name or a generic name?

Cernos is a brand name. The active ingredient it contains is testosterone undecanoate, which is the generic name of the substance.


Q: Can Cernos interfere with lab test results?

Regulatory documents state that this medicine may interfere with the results of certain laboratory tests. For example, it may decrease the level of a protein called Thyroxine-binding Globulin (TBG), which can affect the results of thyroid function tests.


Q: Is Cernos used for fertility issues?

Cernos is indicated for hormone replacement therapy and is not used to treat fertility issues. Regulatory documents state that the use of testosterone products has been associated with a dose-dependent reduction in sperm count (spermatogenesis). This effect may result in male infertility.


Q: Can Cernos be used by people with a history of heart issues?

Official documents define the need for careful evaluation and monitoring of patients who have pre-existing cardiac conditions or risk factors for cardiovascular disease. Regulatory warnings highlight the risk of Major Adverse Cardiovascular Events (MACE) and the potential for increased blood pressure associated with testosterone products.


Q: Is it common to feel a little nauseous after starting Cernos?

Official adverse event profiles for this product list nausea as a reported side effect. While not categorized among the most frequently observed events, it is listed in official documentation as a possible occurrence.


Q: Is it true that Cernos can affect mood or energy levels?

Yes, official safety information notes that this medicine may cause some people to experience changes in mood or behavior, such as becoming agitated or irritable. The label also mentions the potential for more serious psychiatric manifestations, including major depression.

How should Cernos be stored and disposed of?

The storage and disposal of Cernos are defined by regulatory requirements to ensure product stability and safety.

Storage Requirements

Scope Area Official Regulatory Statement
Temperature requirements: Store the capsule form below 30 C. The injection form must also be stored below 30 C.
Environmental conditions: Store in a cool and dry place.
Container rules: The product should be stored in its original container.
Child-safety rules: Keep the product out of the reach and sight of children and pets.

Disposal Instructions

Scope Area Official Regulatory Statement
Disposal instructions: Any unused or expired medicine must be discarded according to local regulations for pharmaceutical waste.
Injection handling: Any unused portions of drug remaining in a single-dose vial must be discarded after use.

Official labeling mandates specific temperature limits and environmental conditions to maintain the medicine’s quality. Furthermore, it is required that the medicine be kept out of the reach of children and stored in its original packaging. Disposal must adhere strictly to local pharmaceutical waste handling guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cernos found in:

A-Z Index: